The best way to conference proceedings by Francis Academic Press

Web of Proceedings - Francis Academic Press
Web of Proceedings - Francis Academic Press

Advances in Antithrombotic Treatment of Coronary Heart Disease Complicated with Atrial Fibrillation

Download as PDF

DOI: 10.25236/icmbmm.2018.69


Zengming Qi

Corresponding Author

Zengming Qi


Atrial fibrillation (AF) is one of the most common clinical arrhythmias and its incidence increases with age. There are approximately 33.5 million cases of atrial fibrillation globally, and it is expected that the number of patients suffering from 2060 will increase by a factor of 2. There are many common risk factors for atrial fibrillation and coronary heart disease, such as age, hypertension, and diabetes. In clinical practice, the two diseases often coexist, and about one-third of patients with atrial fibrillation have coronary heart disease. Atrial thrombosis and coronary thrombosis are different mechanisms, and the two antithrombotic treatment strategies are also different. Antiplatelet drug therapy is the basis and key to secondary prevention of coronary heart disease, and atrial fibrillation relies on oral anticoagulation drugs to reduce the risk of stroke and other thromboembolic events. The difficulty in the treatment of coronary heart disease with atrial fibrillation is that antiplatelet drugs and anticoagulant drugs cannot be completely replaced, and the combined use faces an increased risk of bleeding. Therefore, how to minimize the risk of bleeding while maximizing benefit is the key to the development of coronary heart disease with atrial fibrillation antithrombotic treatment.


Coronary Heart Disease, Atrial Fibrillation, antithrombotic.